about
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiActivin, inhibin and the human breastAbsolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.Prognosis of screen-detected breast cancers: results of a population based studyCancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003.Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraEpidemiological Overview of Hodgkin Lymphoma across the Mediterranean BasinEnteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project.Classic Kaposi's sarcoma in Italy, 1985-1998Pattern of cancer risk in persons with AIDS in Italy in the HAART era.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo ItalThe genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorFertility in female survivors of Hodgkin's lymphoma.Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients.Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility.What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study.Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study.Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry.A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate.
P50
Q28273184-CAB297CC-46C6-4012-AF06-700634FDB66AQ28284993-0F7BE5F8-FF87-4E75-8F5A-5F3630C44CCAQ30966717-CDA27C04-0F01-4D36-9EA0-B8FD5E9C1DCAQ33232320-34D53B4B-95B4-4FCF-947A-23052F24B76DQ33261614-7ECD6979-9E02-4DF5-9D18-60990EE35395Q33311606-0D4C88A3-7BAE-40AD-B1F9-57CE062A7323Q33345685-742DEC10-861A-4B39-A652-7A3CF4D02FD3Q33391919-F859088A-EFC6-4370-9B6C-0323B2462403Q33393849-FBC87EBF-FF4F-403E-8DC4-4D726A39939AQ33558130-B5B48E67-5DC5-40B9-A519-21C3C88F7CBAQ33920125-7E53AC48-0A13-4AAF-B526-D7FB620342F5Q34184665-A7D261E6-DD03-43C3-8EE2-DCEC95462189Q34552954-F3167B59-18EF-4A41-B0CE-9C717E296C48Q34604639-CC63279A-6FEE-4433-93A6-B28FC96BFE2BQ34664223-E64C7674-0592-4D38-AF6C-B30C5AB7026CQ34675007-16944952-9B63-4757-80D4-B846681A2656Q35195231-DFA6DC2C-249C-4C9C-865C-5B69FBC3B11CQ35236063-B8DDA1BA-0A32-4C43-A01C-6FF73216082BQ35999309-ABE903FA-231D-4754-A0C2-A8361097BFB9Q36283790-1D105E52-D630-42E1-A779-DBA4E5A7DA8EQ36441553-C68D0866-C704-46C2-8FCE-A509B1699069Q36716114-3D0FEAED-CDE7-41DD-B900-C874518FBC43Q37126978-9B7EB164-1A0F-4B50-A7A5-34A583FD0FE8Q37203919-24897D7D-DDB2-4A44-A4D4-311E25BFD915Q37216325-9721F42E-867B-498A-9136-D7C228974881Q37306835-5E048450-7721-401E-A97F-5040E690B129Q37877039-AD53BD57-1FD6-4496-B352-7BA4B85EABE1Q37966305-BFC9A2C9-ED24-44F6-9FB9-2C9501C6AFA5Q38122437-60C9AB3F-B405-44FD-8A1C-EDD1BD410714Q38150543-058B57FE-B139-4A4E-A2CC-DC86F00BEEEFQ38190105-EFF68AB8-0E2A-4C74-8C83-289D78E28342Q38246983-DF9B6F42-EE39-46E8-9CDF-1C2A69AEF014Q38417399-32941D0F-2BE0-4217-9CD6-6934811794E0Q38426380-87078245-7BB3-4606-8B68-88638CDFEEF4Q38551290-24793CA1-D78D-4315-8EF4-EB61D11D98E7Q38602677-291B9D35-F766-452B-91E0-358CC352F6E1Q38794103-BDB9B8D7-D71A-4B7D-86DC-D53895122E23Q38852024-519E2948-8718-49B2-978E-054410172C38Q38985250-E29E5C81-9392-4210-9984-4B21E2A205D7Q39336799-636C8A4D-9DD5-4E05-BFF8-B131518E4CB3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Massimo Federico
@ast
Massimo Federico
@en
Massimo Federico
@es
Massimo Federico
@nl
type
label
Massimo Federico
@ast
Massimo Federico
@en
Massimo Federico
@es
Massimo Federico
@nl
prefLabel
Massimo Federico
@ast
Massimo Federico
@en
Massimo Federico
@es
Massimo Federico
@nl
P106
P1153
7101629810
P21
P31
P496
0000-0002-9889-3796